Myriad Genetics Inc
MYGN
In Vitro & In Vivo Diagnostic Substances
Mkt Cap
$2.096BPE
-8.94Debt
$38.7MCash
$105.6MEV
$2.03BFCF
-$142.7MP/E Ratio
-8.94Debt
$38.7MCash
$105.6MEV
$2.03BFCF
-$142.7MCharts data: {"Earnings":[{"time":"2014-06-29","value":176225000},{"time":"2015-06-29","value":80200000},{"time":"2016-06-29","value":125300000},{"time":"2017-06-29","value":21600000},{"time":"2018-06-29","value":130900000},{"time":"2019-06-29","value":4400000},{"time":"2021-12-30","value":-27200000},{"time":"2022-12-30","value":-112000000},{"time":"2023-12-30","value":-263300000}],"Sales":[{"time":"2014-06-29","value":778216000},{"time":"2015-06-29","value":723100000},{"time":"2016-06-29","value":753800000},{"time":"2017-06-29","value":771400000},{"time":"2018-06-29","value":772600000},{"time":"2019-06-29","value":851100000},{"time":"2021-12-30","value":690600000},{"time":"2022-12-30","value":678400000},{"time":"2023-12-30","value":753200000}],"Net Margins":[{"time":"2014-06-29","value":0.22644741305755728},{"time":"2015-06-29","value":0.11091135389296086},{"time":"2016-06-29","value":0.16622446272220748},{"time":"2017-06-29","value":0.028001037075447238},{"time":"2018-06-29","value":0.1694279057727155},{"time":"2019-06-29","value":0.005169780284337916},{"time":"2021-12-30","value":-0.039386041123660585},{"time":"2022-12-30","value":-0.1650943396226415},{"time":"2023-12-30","value":-0.34957514604354756}],"Assets":[{"time":"2014-06-29","value":823814000},{"time":"2015-06-29","value":766200000},{"time":"2016-06-29","value":880500000},{"time":"2017-06-29","value":1224400000},{"time":"2018-06-29","value":1174100000},{"time":"2019-06-29","value":1562700000},{"time":"2021-12-30","value":1320700000},{"time":"2022-12-30","value":1198700000},{"time":"2023-12-30","value":1146500000}],"Stockholders Equity":[{"time":"2014-06-29","value":718998000},{"time":"2015-06-29","value":662100000},{"time":"2016-06-29","value":748100000},{"time":"2017-06-29","value":778200000},{"time":"2018-06-29","value":964900000},{"time":"2019-06-29","value":1088900000},{"time":"2021-12-30","value":967800000},{"time":"2022-12-30","value":885800000},{"time":"2023-12-30","value":783200000}],"ROE":[{"time":"2014-06-29","value":0.24509803921568626},{"time":"2015-06-29","value":0.12112973871016462},{"time":"2016-06-29","value":0.1674909771420933},{"time":"2017-06-29","value":0.027756360832690823},{"time":"2018-06-29","value":0.13566172660379314},{"time":"2019-06-29","value":0.004040775094131693},{"time":"2021-12-30","value":-0.028104980367844597},{"time":"2022-12-30","value":-0.12643937683449988},{"time":"2023-12-30","value":-0.3361848825331971}],"ROA":[{"time":"2014-06-29","value":0.337212040581976},{"time":"2015-06-29","value":0.17606369094231272},{"time":"2016-06-29","value":0.1918228279386712},{"time":"2017-06-29","value":0.040346292061417835},{"time":"2018-06-29","value":0.10109871390852568},{"time":"2019-06-29","value":0.004863377487681577},{"time":"2021-12-30","value":-0.04323464829257212},{"time":"2022-12-30","value":-0.11729373487945274},{"time":"2023-12-30","value":-0.22450937636284343}]}
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
![QDEL Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>QDEL</text></svg>){kind=small}
In the chart Earnings are multiplied by this value.
Earnings Growth -12%
Earnings Stability -49%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 06-2014 | 06-2015 | 06-2016 | 06-2017 | 06-2018 | 06-2019 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 23% | 11% | 17% | 2.8% | 17% | 0.52% | -3.9% | -17% | -35% | -30% |
| ROA | 34% | 18% | 19% | 4% | 10% | 0.49% | -4.3% | -12% | -22% | -21% |
| ROE | 25% | 12% | 17% | 2.8% | 14% | 0.4% | -2.8% | -13% | -34% | -31% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -5.86%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -8.39%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -3.98%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -5.79%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -5.39%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -7.54%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 06-2014 | 06-2015 | 06-2016 | 06-2017 | 06-2018 | 06-2019 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | 1.00 | 0.09 | 3.13 | 0.00 | 0.00 | -0.22 | -0.27 |
| Debt Equity | - | - | - | 0.13 | 0.01 | 0.22 | 0.00 | 0.00 | 0.05 | 0.05 |
| MIN | ||||||||||
| Graham Stability | - | - | - | 17% | 100% | 4.8% | -52% | -310% | - | -310% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -0.27.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -0.27.
What is the Graham’s Stability?
Graham’s Stability measure stands at -3.11.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 06-2015 | 06-2017 | 06-2019 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 0.58% | -0.48% | -4% | 11% | 0.51% |
| Net Income | - | - | - | - | 37% |
| Stockholders Equity | 2.4% | 0.13% | -10% | -12% | -2.3% |
| FCF | - | - | - | - | -14% |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is -0.48%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +0.51%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is +36.55%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +0.13%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -2.26%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -14%.